1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
MeVis Medical Solutions AG

MeVis Medical Solutions AG

M3V.DE
MeVis Medical Solutions AGDE flagDeutsche Börse
23.20
EUR
- -
- -
42.22MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.75
7.42
7.6
8.94
10.19
9.77
9.93
9.41
8.91
10.31
9.53
9.33
- -
9.91
Basic EPS, GAAP
1.26
2.14
2.16
3.76
3.09
4.19
4.43
3.13
2.5
4.28
2.7
2.51
- -
4.43
Free Cash Flow per Basic Share
2.96
4.23
2.59
3.61
3.9
2.71
3.48
1.53
4.99
2.6
3.17
1.56
- -
3.48
Dividend per Share
- -
- -
- -
0.04
- -
5.15
0.89
0.86
3.13
2.5
4.28
2.7
- -
- -
Book Value per Share
-1.61
11.25
13.43
14.03
13.63
3.49
3.49
3.49
3.49
3.49
3.49
3.49
- -
3.49
Tangible Book Value per Share
4.11
6.26
8.5
11.1
11.42
9.74
9.78
9.79
9.79
9.79
9.79
9.79
- -
9.76
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
2
2
2
- -
2
Sales/Revenue/Turnover
13
13
13
16
19
18
18
17
16
19
17
17
16
18
Operating Margin (%)
22.56
34.42
30.02
30.06
43.32
40.56
39.51
36.02
31
34.49
28.28
23.58
14.58
39.51
Depreciation Expense
3
2
2
2
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
2
4
4
7
6
8
8
6
5
8
5
5
3
8
Effective Tax Rate (%)
8.27
6.76
24.9
- -
21.57
1.15
1.04
1.56
1.84
1.11
2.27
2.7
3.45
1.04
Profit Margin (%)
16.21
28.8
28.36
42.06
30.32
42.86
44.66
33.3
28.04
41.52
28.37
26.87
19.71
44.66
Working Capital
7
11
15
17
17
4
4
4
4
5
5
3
3
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
23
26
30
34
33
18
18
18
18
18
18
18
18
18
Return on Invested Capital (%)
11.2
15.74
10.03
- -
15.27
22.72
37.64
33.87
27.51
35.66
26.68
21.68
12.6
37.64
Return on Capital (%)
-143.76
43.78
17.57
- -
17.75
36.23
112.71
89.87
71.64
122.54
78.01
72.01
49.79
112.58
Return on Common Equity (%)
- -
- -
17.47
27.92
22.52
48.89
126.91
89.69
71.48
122.48
77.36
71.71
49.78
126.91

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
49
46
47

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
8
10
7
Cash, Cash Equivalents & STI
2
3
3
Accounts Receivable, Net
3
3
2
Inventories
- -
- -
- -
Total Current Liabilities
3
4
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
17.74%
36.15%
31.44%
Net Income, GAAP
5.33%
-4.73%
-30.58%
Sales/Revenue/Turnover
2.57%
-0.94%
-5.37%
Total Cash Common Dividend
- -
54%
-7.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17
2024
- -
- -
- -
- -
17
2025
- -
- -
- -
- -
16

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.7
2024
- -
- -
- -
- -
2.51
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.28
2024
- -
- -
- -
- -
2.7
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Marcus Kirchhoff
Full Time Employees
100
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
Caroline-Herschel-Str. 1 Bremen Germany 28359
IPO Date
Nov 16, 2007
Website
mevis.de
Similar Companies
Schrödinger, Inc. (SDGR)
GeneDx Holdings Corp. (WGSWW)
VSee Health, Inc. (VSEEW)
RaySearch Laboratories AB (publ) (RSLBF)
Modern Mobility Aids, Inc. (MDRM)
MRT Inc. (6034.T)
Business
MeVis Medical Solutions AG (M3V.DE) develops and markets software solutions for medical imaging analysis and visualization, primarily focused on diagnostic support in radiology and oncology. The company offers advanced image processing tools including MeVisLab, a modular platform for creating customized medical image processing applications; Riverain Medical's ClearRead Detect and ClearRead Compare for chest CT and X-ray analysis to aid in lung nodule and lesion detection; Fraunhofer MEVIS research software for liver and lung applications; and services such as customized software development, regulatory validation, and clinical workflow integration. These products serve healthcare providers, medical device manufacturers, and research institutions worldwide, with operations spanning Europe, North America, and Asia; MeVis Medical Solutions AG was founded in 1995 and is headquartered in Bremen, Germany, as a subsidiary of Fraunhofer-Gesellschaft. In recent developments, the company completed the acquisition of Riverain Medical in 2023, expanding its AI-powered chest imaging portfolio with FDA-cleared technologies for early lung disease detection, followed by CE marking approvals in Europe for ClearRead products in 2024. MeVis continues to advance its oncology-focused software through partnerships with leading radiology systems providers and participation in Fraunhofer research initiatives on multimodal imaging. No major funding rounds, name changes, or operational reorganizations have been reported in the last two years, with strategic emphasis on integrating acquired technologies into global sales channels and enhancing AI capabilities for precision diagnostics.